Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

NCT00334438 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

BIOLOGICAL: rituximab
DRUG: bortezomib
RADIATION: yttrium Y 90 ibritumomab tiuxetan
RADIATION: Indium 111 ibritumomab tiuxetan

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]